FORM OF INDEMNIFICATION AGREEMENTIndemnification Agreement • August 14th, 2017 • Altimmune, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of , 20 between Altimmune Inc. a Delaware corporation (the “Company”), and [ ] (“Indemnitee”).
Second Restated License Agreement VAXIN – CRUCELLLicense Agreement • August 14th, 2017 • Altimmune, Inc. • Pharmaceutical preparations
Crucell Holland B.V., a corporation organized under the laws of the Netherlands, having offices located at Archimedesweg 4, 2333 CN, Leiden, the Netherlands, (hereinafter referred to as “CRUCELL”); and
CONVERTIBLE PROMISSORY NOTE PURCHASE AGREEMENTConvertible Promissory Note Purchase Agreement • August 14th, 2017 • Altimmune, Inc. • Pharmaceutical preparations • Delaware
This CONVERTIBLE PROMISSORY NOTE PURCHASE AGREEMENT (this “Agreement”), dated as of January 18, 2017, by and among Altimmune, Inc., a Delaware corporation (the “Company”), the purchasers listed on the Schedule of Purchasers attached as Exhibit A-1 hereto on the date hereof (each a “Purchaser” and together the “Purchasers”). The Parties hereby agree as follows:
AMENDMENT NO. 1 TO SECOND RESTATED LICENSE AGREEMENTLicense Agreement • August 14th, 2017 • Altimmune, Inc. • Pharmaceutical preparations
This Amendment No. 1 to the Second Restated License Agreement is made and effective as of September 25, 2015 by and between Crucell Holland B.V., a corporation organized under the laws of the Netherlands, having offices at Archimedesweg 4-6, 2333 CN Leiden, the Netherlands (“CRUCELL”) and Altimmune Inc., a Delaware corporation, having offices located at 19 Firstfield Road, Gaithersburg, Maryland, USA 20878, formerly VAXIN INC., a Delaware corporation, having offices located at 1500 First Avenue North, Birmingham, Alabama, U.S.A. (“VAXIN”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • August 14th, 2017 • Altimmune, Inc. • Pharmaceutical preparations • Maryland
This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into as of December 7, 2015, by and between William J. Enright (“Enright”) and Altimmune Inc. (f/k/a Vaxin, Inc.), a Delaware corporation (“Altimmune”). This Agreement will become effective upon the date of the underwriting agreement between Altimmune and the underwriter(s) managing the initial public offering of Altimmune’s common stock (the “IPO”), pursuant to which such common stock is priced for the IPO (the “Effective Date”); provided that if (i) Altimmune does not complete an IPO on or prior to the one year anniversary of the date hereof or (b) Enright does not remain continuously employed by Altimmune from the date hereof through the Effective Date, this Agreement shall be void ab initio (i.e., it shall never take effect) and the Prior Employment Agreement (as defined below) shall remain in full force and effect.
EMPLOYMENT AGREEMENTEmployment Agreement • August 14th, 2017 • Altimmune, Inc. • Pharmaceutical preparations • Maryland
This EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into as of April 4, 2016 (the “Effective Date”) by and between Sybil Tasker (“Tasker”) and Altimmune, Inc., a Delaware corporation (“Altimmune”).
First Amendment to the Employment Agreement between Altimmune, Inc. and Elizabeth CzerepakEmployment Agreement • August 14th, 2017 • Altimmune, Inc. • Pharmaceutical preparations
This First Amendment to the Employment Agreement, effective as of January 18, 2017 (this “Amendment”), is by and between Altimmune, Inc. (“Altimmune”) and Elizabeth Czerepak (“Czerepak”).
First Amendment to the Amended and Restated Employment Agreement between Altimmune, Inc. and William J. EnrightEmployment Agreement • August 14th, 2017 • Altimmune, Inc. • Pharmaceutical preparations
This First Amendment to the Amended and Restated Employment Agreement, effective as of January 18, 2017 (this “Amendment”), is by and between Altimmune, Inc. (“Altimmune”) and William J. Enright (“Enright”).
EMPLOYMENT AGREEMENTEmployment Agreement • August 14th, 2017 • Altimmune, Inc. • Pharmaceutical preparations • Maryland
This EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into as of December 7, 2015 (the “Effective Date”) by and between M. Scot Roberts (“Roberts”) and Altimmune, Inc. (f/k/a Vaxin, Inc.), a Delaware corporation (“Altimmune”).
EMPLOYMENT AGREEMENTEmployment Agreement • August 14th, 2017 • Altimmune, Inc. • Pharmaceutical preparations • Maryland
This EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into as of December 7, 2015 (the “Effective Date”) by and between Elizabeth Czerepak (“Czerepak”) and Altimmune, Inc. (f/k/a Vaxin, Inc.), a Delaware corporation (“Altimmune”).
AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • August 14th, 2017 • Altimmune, Inc. • Pharmaceutical preparations • Alabama
This Amended and Restated Exclusive Agreement (this “Agreement”) is made and is effective as of June 2, 2014 (the “Effective Date”) between The UAB Research Foundation (“UABRF”) and Vaxin Inc. (the “Licensee”) and amends and restates in its entirety the Exclusive License Agreement between the Parties dated March 1, 1998 (the “Original License”).
First Amendment to Amended and Restated Exclusive License AgreementExclusive License Agreement • August 14th, 2017 • Altimmune, Inc. • Pharmaceutical preparations
This First Amendment to Amended and Restated Exclusive License Agreement (this “First Amendment”) is made effective as of October 16, 2015 (the “First Amendment Effective Date”) by and between Altimmune, Inc. (f/k/a Vaxin Inc.), a (“Licensee”) and The UAB Research Foundation, a non-profit 501(c)(3) corporation incorporated in the State of Alabama and an affiliate of UAB (“UABRF”). Company and UABRF may be each individually referred to as a “party” and collectively, the “parties”.
